PEPTIDE GUIDE

What Is CJC-1295 DAC?

CJC-1295 DAC is an experimental peptide built from a modified 29-amino-acid fragment of growth hormone-releasing hormone, the natural signal that tells the pituitary gland to release growth hormone. An additional Drug Affinity Complex, shortened to DAC, allows it to attach to albumin in the blood and remain active far longer than the natural hormone fragment.

That description needs three qualifications. CJC-1295 DAC is not growth hormone. It has not been approved as a medicine by the US Food and Drug Administration, normally shortened to FDA, or by the UK Medicines and Healthcare products Regulatory Agency. Its human evidence consists mainly of small, short studies in healthy adults that measured hormone levels rather than improvements in health, body composition, strength or recovery.

Research statusInvestigational GHRH analogue with limited early human evidence
Development nameDAC:GRF
Peptide typeModified GHRH(1-29) analogue with a DAC unit
Human evidenceSmall studies in healthy adults
Last reviewedSeptember 2026
THE SHORT ANSWER

CJC-1295 DAC is a long-acting laboratory-made analogue built from the first 29 amino acids of human growth hormone-releasing hormone and an added albumin-binding unit. The DAC group is designed to form a bond with albumin, a common blood protein, which gave the compound an estimated half-life of 5.8 to 8.1 days in an early human study. Small controlled studies found prolonged increases in growth hormone and insulin-like growth factor 1, known as IGF-1. They did not establish treatment benefits. Development did not produce an approved medicine, a Phase 2 trial in people with HIV-associated abdominal fat was terminated, and FDA has identified safety and product-characterisation concerns.

What exactly is CJC-1295 DAC?

The compound is based on human growth hormone-releasing hormone, abbreviated to GHRH. GHRH is a 44-amino-acid hormone made in the hypothalamus, a small part of the brain involved in hormone control. It travels a short distance to the pituitary gland at the base of the brain and activates the GHRH receptor on cells that make growth hormone.

The first 29 amino acids of GHRH contain the part needed to activate that receptor. Researchers therefore used this shorter section as a starting point for several medicines and experimental compounds. Sermorelin was a pharmaceutical version of GHRH(1-29), meaning amino acids 1 to 29. Tesamorelin is a 44-amino-acid GHRH analogue used in an approved medicine for excess abdominal fat in adults with HIV-associated lipodystrophy.

CJC-1295 DAC takes the 29-amino-acid fragment and changes four positions. These substitutions are intended to make the peptide less vulnerable to enzymes that rapidly cut up natural GHRH. A specially modified lysine is then added at the end. This carries a maleimidopropionyl group, the reactive part of the Drug Affinity Complex.

Once the compound enters the bloodstream, the DAC group can form a covalent bond with a free sulphur-containing site on albumin. Covalent means that the atoms become joined by a strong chemical bond. Albumin is the most abundant protein in blood plasma and circulates for much longer than an unprotected GHRH fragment. Attaching the peptide to albumin therefore slows its removal.

Why do the names cause confusion?

The name CJC-1295 is used for several chemically different materials. In the original development programme, CJC-1295 referred to the albumin-binding compound and was also called DAC:GRF. GRF means growth hormone-releasing factor, an older name for GHRH.

The research-peptide market later began using “CJC-1295 No DAC” for Mod GRF 1-29. That material is generally described as the same modified 29-amino-acid backbone without the albumin-binding lysine and maleimide group. Calling both products CJC-1295 makes published research easy to misapply.

The chemical form creates another layer of complexity. A peptide may be described as a free base or supplied with a counterion such as acetate or trifluoroacetate, often shortened to TFA. Counterions balance electrical charge in the solid material. They can affect mass, analysis and formulation even when the central peptide has the same sequence.

FDA assessed five names separately in 2024: CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate and CJC-1295 DAC TFA. The agency found inconsistent identifiers, structures and certificates in the nomination material. It also found that the published human studies appeared to use the DAC form manufactured by ConjuChem, but did not clearly specify a salt.

For this guide, CJC-1295 DAC means the long-acting albumin-binding compound studied by ConjuChem. It does not mean Mod GRF 1-29, a product carrying an unclear label or every material sold online as CJC-1295.

NameWhat it usually meansDirect human evidence
CJC-1295 DACModified GHRH(1-29) backbone with an albumin-binding Drug Affinity ComplexSmall short studies in healthy adults
DAC:GRFOriginal development name for CJC-1295 DACSame early studies
CJC-1295 No DACMarket name generally used for Mod GRF 1-29 without the albumin-binding groupNo direct clinical study of the marketed form located
CJC-1295 free base or acetateNames that may refer to the 29-amino-acid non-DAC sequenceFDA found no human clinical safety or effectiveness evidence for these specific forms

How does the normal growth hormone system work?

Growth hormone is released in pulses rather than at a steady rate. The strongest pulses often occur during sleep, although timing varies with age, sex, nutrition, exercise, stress and health. Two signals from the hypothalamus help control the pattern. GHRH encourages release, while somatostatin restrains it.

The pituitary gland releases growth hormone into the bloodstream. Growth hormone then acts directly on some tissues and also tells the liver and other tissues to produce IGF-1. IGF-1 is a hormone involved in growth, tissue maintenance and metabolism. Its blood concentration changes more slowly than individual growth hormone pulses, which is why it is often used as a broader marker of activity in this system.

Feedback loops prevent the system from operating in only one direction. Higher growth hormone and IGF-1 activity can reduce further release through signals involving the hypothalamus and pituitary. Natural pulses also depend on the pituitary having a usable store of growth hormone and functioning GHRH receptors.

CJC-1295 DAC activates the GHRH receptor. It does not replace growth hormone, and it cannot make an absent or severely damaged pituitary behave normally. FDA noted that people with complete growth hormone deficiency would not be expected to respond to a growth hormone secretagogue such as a CJC-1295-related substance. A secretagogue is a substance that prompts a gland to release something it already produces.

Is CJC-1295 growth hormone or a steroid?

No. Growth hormone is a 191-amino-acid protein produced by the pituitary gland. CJC-1295 DAC is a smaller GHRH-receptor agonist. An agonist is a molecule that activates a receptor. The compound is intended to prompt the body to release its own growth hormone rather than provide growth hormone itself.

It is also not an anabolic steroid. Anabolic steroids are compounds related to testosterone that act through androgen receptors. CJC-1295 DAC acts through the GHRH receptor. Both pathways can attract performance-related claims, but they are biologically different.

This does not make CJC-1295 DAC a gentle or naturally self-limiting alternative. A long-acting signal can keep average hormone exposure above normal for days. In the main human study, IGF-1 remained raised for 9 to 11 days after one administration and for up to 28 days after repeated administrations. The fact that the pituitary makes the released growth hormone does not remove risks associated with altering the system.

What is CJC-1295 DAC made from?

The peptide portion is assembled from amino-acid raw materials. Most are the same L-amino acids used in human proteins. The second position contains D-alanine, a mirror-image form of alanine that is less readily recognised by some peptide-cutting enzymes. Other substitutions replace asparagine at position 8 with glutamine, glycine at position 15 with alanine and methionine at position 27 with leucine.

The C-terminal end, meaning the end with a free carboxyl group during ordinary protein synthesis, is amidated. Amidation replaces that terminal group with an amide and can alter stability. The DAC component uses a lysine carrying a maleimidopropionyl group. That maleimide can react with a free thiol, a sulphur-containing chemical group, on albumin.

The raw materials used for chemical manufacture are not taken from human pituitary tissue. They are protected amino-acid derivatives, a solid resin, coupling reagents, solvents and the chemicals needed to add the terminal modifications. “Synthetic” here means that the sequence is assembled through controlled chemical reactions.

How is CJC-1295 DAC synthesised and manufactured?

CJC-1295 DAC can be assembled by solid-phase peptide synthesis. The growing peptide is anchored to an insoluble resin. Protected amino acids are added one at a time in the required order. Protecting groups temporarily cover reactive parts of each amino acid so that the next peptide bond forms in the intended place.

After the 29-amino-acid backbone has been built, the specialised lysine and maleimidopropionyl component must be incorporated correctly. The peptide is then removed from the resin and the remaining protecting groups are cleared. Preparative high-performance liquid chromatography, usually shortened to HPLC, separates the intended peptide from shorter chains, altered sequences and reaction by-products.

Analytical HPLC estimates purity by separating components in a sample. Mass spectrometry checks molecular mass and can help confirm sequence and modifications. Additional methods are needed to measure water, residual solvents, counterions and aggregates. An aggregate is a group of peptide molecules that has clumped together.

For a material intended for injection, chemical identity is only part of quality. Manufacture would also need validated controls for sterility, endotoxins, visible particles, sub-visible particles, container closure, concentration, stability and degradation. Endotoxins are inflammatory bacterial components that can remain even when living bacteria are absent.

The albumin-binding group creates particular analytical questions. A product may contain the right 29-amino-acid mass but lack the DAC group, carry it at the wrong site or contain reactive impurities. FDA highlighted peptide-related impurities, aggregation, immunogenicity and active-ingredient characterisation as concerns for compounded CJC-1295. Immunogenicity means the ability of a material to trigger an immune response.

When was CJC-1295 first documented?

The scientific story starts before the CJC name. In 1982, two research groups reported a growth hormone-releasing factor isolated from a pancreatic tumour in a person with acromegaly. Acromegaly is a condition caused by excessive growth hormone activity in an adult. Researchers then identified the 44-amino-acid human hormone and showed that its first 29 amino acids retained receptor activity.

During the 1980s and 1990s, researchers made modified GHRH fragments to resist rapid enzymatic breakdown. ConjuChem, a Canadian biotechnology company developing albumin-binding drug technology, applied its Drug Affinity Complex approach to a modified GHRH(1-29) backbone.

The name CJC-1295 appeared in peer-reviewed development papers in 2005. A rat study described how the compound formed an albumin bioconjugate and lasted longer in circulation. Human pharmacology papers followed in 2006. A planned 12-week Phase 2 study in people with HIV-associated visceral obesity was terminated, and the development programme did not produce an approved medicine.

YearDevelopment
1982Human growth hormone-releasing factor was isolated and characterised
1980sThe active 1-to-29 fragment and early enzyme-resistant analogues were studied
1990sStructure and stability research developed modified GHRH fragments further
2005CJC-1295 was described as an albumin-binding, long-lasting GHRH analogue in rats
2006Controlled studies reported prolonged growth hormone and IGF-1 changes in healthy adults
2006A Phase 2 HIV-associated visceral-obesity study was terminated
2009Researchers used stored human samples to examine blood-protein changes after CJC-1295
2010A doping laboratory identified a 29-amino-acid CJC-1295 product seized by authorities
2016Researchers published a mass-spectrometry method for GHRH analogues including CJC-1295
2024FDA evaluated five CJC-1295-related bulk substances and proposed against 503A-list inclusion
2026FDA continued to list CJC-1295 among compounded substances presenting significant safety concerns

How does the Drug Affinity Complex change the peptide?

Natural GHRH and unprotected GHRH(1-29) are cleared quickly. Enzymes cut peptide bonds and the kidneys remove small molecules from the circulation. A short exposure can still trigger a growth hormone pulse, but it limits how long the signal lasts.

CJC-1295 DAC was designed to solve that problem inside the body. The maleimide group reacts mainly with cysteine 34 on albumin. Cysteine is an amino acid containing sulphur. Albumin's cysteine 34 has a free thiol that is available for bonding.

The resulting albumin-peptide bioconjugate is much larger than the free peptide. It is less readily filtered by the kidneys and is partly protected from enzymes. The GHRH-like portion can still reach and activate receptors on pituitary cells.

The design does not guarantee that every molecule binds only albumin. FDA noted that the reactive DAC group might also interact with thiols on other proteins and contribute to unintended effects. The long duration also means that an unwanted effect cannot be ended simply by withholding the next administration. The material already bound in circulation may remain active for days.

What did the preclinical studies show?

Preclinical means research conducted before or outside therapeutic trials in patients. It includes laboratory receptor work and animal experiments. These studies can show whether a proposed mechanism is plausible, but they cannot establish a medical benefit in people.

In the 2005 development paper, researchers studied CJC-1295 in laboratory receptor systems and rats. Blood analysis showed an immunoreactive CJC-1295 species at the position expected for albumin. It appeared within 15 minutes and remained detectable beyond 24 hours. Growth hormone rose after the compound was given, while the CJC-1295 signal remained in circulation after growth hormone had moved back towards baseline.

A 2006 study used mice genetically unable to produce normal GHRH. These animals have poor growth and abnormal body composition. Repeated CJC-1295 administration increased growth, body length and IGF-1 and changed pituitary measures. A knockout mouse is an animal in which a gene has been disabled for research. The model shows that the compound can activate the pathway when natural GHRH is absent. It does not show that it improves recovery, muscle growth or ageing outcomes in healthy people.

FDA's later assessment found additional animal toxicology signals. Repeated daily administration in rats and dogs was associated with injection-site haemorrhage, inflammation and tissue death at the studied higher exposures. FDA also discussed genetic-toxicity signals and the absence of long-term cancer studies. These findings do not prove the same events would occur in a person, but they prevent the animal record from being described as uniformly reassuring.

What did the main human study examine?

The main paper reported two randomised, double-blind, placebo-controlled, ascending-dose studies. Randomised means participants were assigned by chance. Double-blind means neither participants nor the study staff assessing them knew who received the active compound. A placebo is a matching inactive preparation used to show what happens without the test compound.

The participants were healthy adults aged 21 to 61, not people being treated for growth hormone deficiency. The first study followed participants for 28 days after one administration. The second followed them for 49 days after two or three administrations given one or two weeks apart.

The research measured pharmacokinetics and pharmacodynamics. Pharmacokinetics describes what the body does to a compound, including how its blood concentration changes. Pharmacodynamics describes what the compound does to the body, here measured mainly through growth hormone and IGF-1.

The studies did not test whether participants gained useful muscle, lost fat, recovered from injury, slept better, felt younger or improved physical performance. A hormone change was the outcome, not a demonstrated health benefit.

Documented administration levels

The following levels identify the experiments. They are not a dosing guide and should not be converted into a personal protocol.

Study groupDocumented research exposurePurpose
Single-dose study30, 60, 125 or 250 micrograms per kilogram by subcutaneous administrationMeasure concentration, hormone response and short-term safety across ascending levels
Repeated-dose group 130 micrograms per kilogram on days 0 and 14Examine accumulation and duration
Repeated-dose group 260 micrograms per kilogram on days 0 and 14Examine accumulation and duration at a higher level
Repeated-dose group 330 micrograms per kilogram on days 0, 7 and 14Examine weekly exposure
Repeated-dose group 420 micrograms per kilogram on days 0, 7 and 14Examine weekly exposure at a lower level

A microgram is one millionth of a gram. “Per kilogram” means that the research amount was scaled to body weight. It does not make the values transferable to an unapproved product. The original study used a sponsor-manufactured compound with a defined programme, monitoring and eligibility criteria.

What happened to growth hormone and IGF-1?

After one administration, average growth hormone concentrations increased in a level-related manner. The paper reported rises of about twofold to tenfold that lasted six days or more. Average IGF-1 concentrations rose by about 1.5-fold to threefold and remained increased for 9 to 11 days.

The estimated half-life was 5.8 to 8.1 days. Half-life is the time required for the measured amount in the body to fall by half. It does not mean that every effect ends after one half-life. Repeated exposure can lead to accumulation when the previous amount has not been cleared.

After repeated administrations, mean IGF-1 remained above baseline for up to 28 days. Baseline is the measurement taken before the experimental compound. At the highest single level, some participants' IGF-1 concentrations exceeded the normal range adjusted for age and sex.

These results show that CJC-1295 DAC can produce a prolonged biological signal in healthy adults. They do not show that raising the signal improves health. IGF-1 is a biomarker, meaning a measurable biological indicator. A biomarker can confirm that a pathway changed without proving that a person experienced a worthwhile outcome.

Does growth hormone remain pulsatile?

A separate paper examined 12 healthy men after one administration of CJC-1295. Researchers took blood every 20 minutes overnight for 12 hours. This dense sampling allowed them to examine peaks, troughs and the timing of growth hormone release.

Participants had received 60 or 90 micrograms per kilogram. Average growth hormone increased by 46% from baseline, and average trough concentrations increased about 7.5-fold. A trough is the low point between peaks. The release pattern still contained pulses rather than becoming a completely flat, continuous output.

This finding is often described as proof that CJC-1295 preserves normal physiology. That goes too far. The study showed pulses in a small group during a limited overnight sampling period. It also showed that the low points between pulses were markedly raised. Preserving peaks does not mean total exposure remains normal.

What did the blood-protein study add?

A 2009 paper analysed stored serum from healthy adults exposed to CJC-1295. Serum is the liquid part of blood after clotting. The researchers used proteomics, a set of methods for measuring many proteins in a sample, to look for markers of growth hormone and IGF-1 activity.

They reported changes in several circulating proteins after activation of the pathway. The purpose was to identify possible biomarkers, not to test a treatment outcome. The study did not show that the protein changes improved health or performance.

This paper matters because it confirms that a prolonged change in the growth hormone and IGF-1 system can affect more than the two headline hormone measurements. It also shows why a broad biological response requires broader safety evaluation. A serum-protein pattern is not evidence of anti-ageing, muscle gain or recovery.

Was CJC-1295 tested in a Phase 2 trial?

Yes, but the trial did not establish a benefit. ConjuChem registered a multicentre Phase 2 study in people with HIV-associated visceral obesity. Visceral fat is fat stored around internal abdominal organs. Phase 2 usually means an intermediate clinical stage intended to explore whether a medicine works in the target condition while continuing safety assessment.

The planned study was randomised, double-blind and placebo-controlled. It was intended to compare 12 weeks of CJC-1295 with placebo. The record lists the study as terminated and provides no results establishing effectiveness.

FDA's 2024 review noted reports that the programme was stopped after the death of a participant. The agency also noted an account that the attending physician considered underlying coronary artery disease and plaque rupture the most likely explanation, rather than the study treatment. Without a completed trial report, the event should not be presented either as proof that CJC-1295 caused the death or as proof that it was unrelated.

The reliable conclusion is narrower: the trial ended early, did not provide evidence of benefit and did not lead to an approved treatment for HIV-associated visceral fat.

What benefits are actually supported?

The human evidence supports one central finding: a sponsor-manufactured CJC-1295 DAC compound produced prolonged increases in growth hormone and IGF-1 in small studies of healthy adults.

It does not establish the consumer claims commonly attached to the name.

ClaimWhat the evidence showsWhat remains unknown
Raises growth hormoneSmall controlled studies found increased average and trough growth hormoneClinical benefit and long-term safety
Raises IGF-1Small controlled studies found prolonged, level-related increasesWhether raising IGF-1 improves outcomes in people without a diagnosed deficiency
Builds muscleNo controlled patient trial demonstrated increased useful muscle mass or strengthMagnitude, durability and safety of any body-composition effect
Reduces body fatThe relevant Phase 2 trial was terminated without evidence of benefitEffect on visceral or total fat
Improves sleepNo direct controlled sleep trial was identifiedSleep quality, sleep architecture and next-day function
Speeds recoveryNo controlled human injury or rehabilitation study was identifiedPain, tissue healing, return to activity and re-injury
Reverses ageingNo anti-ageing trial demonstrated improved healthspan or lifespanLong-term balance of benefit and harm

Growth hormone and IGF-1 have real biological roles. That does not mean that increasing them above an individual's normal pattern is beneficial. The Orentra research methodology gives more weight to controlled outcomes that matter to patients than to pathway activation alone.

What side effects were reported in the human studies?

The main publication reported no serious adverse reactions in its short observation periods. “No serious adverse reactions” does not mean “no side effects” or “proven safe”. Most participants received only one administration, the sample was small and follow-up was short compared with the long-term uses later promoted online.

FDA's study-level review provides more detail. In the first study, adverse events were reported in 33 of 35 actively treated participants and two of seven placebo participants. Injection-site irritation, redness, firmness, pain or itching occurred in about 70% of active participants. Temporary raised rashes at the site occurred in almost 30%.

Headache was reported in 63% of active participants and 14% of placebo participants. Diarrhoea occurred in 43% of active participants in the first study. Flushing, warmth and temporary low blood pressure, grouped as systemic vasodilatory reactions, occurred in about 30% of active participants and were more common at higher experimental levels.

In the repeated-exposure study, local reactions were reported in all active participants. Flushing occurred only in active participants and generally began within 30 minutes before resolving within one to two hours.

These figures belong to specific early studies and should not be treated as a precise risk estimate for an unregulated product. Product identity, impurities, concentration and sterility can add risks that were not present in the sponsor's material.

What longer-term risks are uncertain?

Long-term safety has not been established. FDA compared the pathway with approved products that raise growth hormone activity and noted potential concerns including glucose intolerance, diabetes, fluid retention, raised pressure inside the skull, effects on thyroid and adrenal function, pancreatitis and the growth of existing tumours. This comparison does not prove that CJC-1295 causes every listed event. It explains why a compound that stimulates the same biological axis needs adequate testing.

Growth hormone can reduce insulin sensitivity, meaning the body may need more insulin to control blood glucose. IGF-1 also supports cell growth and survival. That role is normal and necessary, but prolonged elevation creates questions for people with an existing or previous tumour. The available CJC-1295 trials were too small and short to measure uncommon metabolic or cancer outcomes.

FDA found no two-year cancer studies for the evaluated forms and discussed pituitary enlargement and tumour findings in animal models with persistent GHRH overexpression. Overexpression means that a gene produces much more of a signal than usual. Those models are not the same as intermittent human exposure, but they support the need for long-term investigation.

Antibody formation is another unknown. An immune response might target the experimental peptide, the albumin-bound complex or, in a worst case, related natural hormones. Aggregation and impurities can increase immunogenicity. The published studies do not provide a modern, long-term antibody programme across a large population.

What are the regulatory limits?

CJC-1295 DAC is not an FDA-approved medicine. It is not an approved treatment for growth hormone deficiency, obesity, muscle loss, injury recovery, sleep problems or ageing.

In December 2024, FDA presented five CJC-1295-related bulk substances to its Pharmacy Compounding Advisory Committee. Section 503A is a part of US law that can permit traditional pharmacies to compound medicines for identified patients under defined conditions. Consideration for the 503A bulk-substances list is not drug approval.

FDA proposed that none of the five forms should be added to that list. Its reasons included unclear chemical characterisation, limited evidence of historical compounding, nonclinical safety concerns, little clinical safety information and no evidence of effectiveness for growth hormone deficiency. FDA's current safety page also states that compounded CJC-1295 may present immunogenicity, impurity and active-ingredient-characterisation risks and notes serious adverse events including increased heart rate and systemic vasodilatory reactions.

A compounded product is not the same as an FDA-approved medicine. It does not pass the same pre-market review for safety, effectiveness, manufacturing consistency and labelling.

Is CJC-1295 prohibited in sport?

Yes. The World Anti-Doping Agency, normally shortened to WADA, lists growth hormone-releasing factors under section S2.2.4 of the 2026 Prohibited List. The examples include CJC-1295. Substances in this class are prohibited at all times, both in and out of competition, for athletes governed by the World Anti-Doping Code.

Anti-doping laboratories have developed mass-spectrometry methods for CJC-1295 and related GHRH analogues. In 2009, Norwegian authorities submitted an unknown preparation for analysis. Researchers identified a 29-amino-acid C-terminally amidated peptide consistent with CJC-1295. This demonstrated that illicitly supplied products had entered the market. It did not show that every product carrying the name contains the same molecule or the original DAC form.

Why is online product identity a separate problem?

The published human studies used material made for ConjuChem's clinical programme. An online vial is not validated by having the same name on its label.

There are at least four questions: whether the vial contains the DAC or non-DAC form, whether the amino-acid sequence is correct, whether the claimed quantity is present and whether the finished material is sterile and free from unacceptable endotoxin. A certificate showing one chromatogram cannot answer every question.

FDA found naming inconsistencies even in formal nomination documents. One identifier associated the name CJC-1295 with the structure of the DAC form, while some molecular information corresponded to the non-DAC backbone. If professional regulatory submissions can mix the forms, a consumer label should not be treated as chemical proof.

The albumin-reactive maleimide also means that an incompletely characterised impurity may behave differently from an ordinary short peptide. Identity, site of modification and reactive by-products all matter.

CompoundMain structureDuration strategyRegulatory positionEvidence boundary
CJC-1295 DACModified GHRH(1-29) plus albumin-binding DACCovalent attachment to albuminUnapprovedSmall early studies in healthy adults
Mod GRF 1-29Modified GHRH(1-29) without DACAmino-acid substitutions intended to slow enzymatic breakdownUnapprovedNo direct clinical programme located
SermorelinNative-sequence GHRH(1-29) amideShort-acting fragmentFormer US medicine, no current approved Geref productHistorical diagnostic and paediatric research does not validate current compounded products
TesamorelinModified full-length 44-amino-acid GHRH analogueN-terminal modification improves stabilityActive ingredient in approved EGRIFTA productsApproved only for the labelled indication and product
IpamorelinFive-amino-acid ghrelin-receptor agonistDifferent receptor pathwayUnapprovedLimited human development research

These compounds should not share evidence simply because they can all increase growth hormone. Structure, receptor interaction, duration, formulation, population and manufacturing quality affect both benefit and risk.

What would stronger evidence require?

A credible development programme would first define one exact active ingredient and formulation. It would need validated manufacturing methods, impurity limits, sterility controls and stability data.

Early clinical work would need to characterise exposure, immune responses, glucose control, fluid balance, cardiovascular effects and the full hormone profile. It would also need enough follow-up to account for a multi-day half-life and accumulation.

Later trials would have to enrol people with a clearly defined condition, compare the product with placebo or an established treatment and measure outcomes that matter. For growth hormone deficiency, that could include validated body-composition, quality-of-life and metabolic outcomes under specialist assessment. For any claimed recovery use, it would require injury-specific function and return-to-activity measures rather than hormone changes alone.

Longer studies would be required to assess diabetes, pituitary effects, tumour-related outcomes and antibodies. Separate studies would be needed for children. Evidence from healthy adults after one exposure cannot answer those questions.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is CJC-1295 DAC an approved medicine?

No. CJC-1295 DAC has not been approved by FDA as a medicine. Early studies showed prolonged hormone changes, but the development programme did not establish an approved treatment.

What does DAC mean in CJC-1295?

DAC means Drug Affinity Complex. It is an added reactive chemical group designed to bind the peptide to albumin in the blood and extend its circulation time.

Is CJC-1295 DAC the same as CJC-1295 No DAC?

No. The DAC form carries an albumin-binding modification. “CJC-1295 No DAC” is generally used for Mod GRF 1-29, a shorter-acting modified GHRH fragment without that component.

Is CJC-1295 DAC growth hormone?

No. It is a GHRH-receptor agonist intended to prompt the pituitary to release growth hormone. Growth hormone itself is a different 191-amino-acid protein.

How long did CJC-1295 DAC last in the human study?

The estimated half-life was 5.8 to 8.1 days. Growth hormone remained increased for six days or more and IGF-1 for 9 to 11 days after one administration in the published study.

Did the studies prove muscle growth or fat loss?

No. The main studies measured compound concentrations, growth hormone, IGF-1 and short-term adverse events. They did not establish gains in strength or useful muscle, and the Phase 2 visceral-obesity trial was terminated without evidence of benefit.

Were the published administration levels medical recommendations?

No. They were experimental levels used in small controlled studies. Reporting them identifies the research and does not provide a personal dose or protocol.

What side effects were reported?

Reported events included frequent injection-site reactions, headache, diarrhoea, flushing, warmth and temporary low blood pressure. The studies were too small and short to define uncommon or long-term risks.

Can the early studies establish long-term safety?

No. Most participants received one administration, sample sizes were small and follow-up was short. Long-term metabolic, immune, pituitary and tumour-related risks remain uncertain.

Is a compounded CJC-1295 product FDA approved?

No. Compounded drugs are not FDA approved. FDA has raised concerns about CJC-1295 identity, impurities, immunogenicity and adverse events.

Is CJC-1295 DAC prohibited in sport?

Yes. WADA lists CJC-1295 among prohibited growth hormone-releasing factors. It is prohibited at all times for athletes subject to the World Anti-Doping Code.

Does preserving growth hormone pulses mean the response is normal?

No. A small study found that pulses remained visible, but average and trough growth hormone increased. A pulsatile pattern can still involve prolonged exposure outside an individual's normal range.

Why can the CJC-1295 label be unreliable?

The name is used for DAC and non-DAC materials, different salt forms and products with unclear characterisation. A label alone cannot establish sequence, modification, quantity, sterility or purity.

RESEARCH AND MEDICAL NOTICE

This guide explains published research and regulatory information. It does not recommend CJC-1295 DAC, provide a dose, describe administration or replace medical advice. CJC-1295 DAC is an unapproved compound with limited human evidence and unresolved long-term safety questions.

RESEARCH LIBRARY

Sources

Regulatory and trial recordsFDA
FDA: evaluation of CJC-1295-related bulk drug substances for the 503A Bulks ListOpen source →
Regulatory and trial recordsFDA
FDA: compounded bulk substances that may present significant safety risksOpen source →
Regulatory and trial recordsFDA
FDA: bulk drug substances used in compounding under section 503AOpen source →
Regulatory and trial recordsClinicalTrials.gov
ClinicalTrials.gov: NCT00267527 Phase 2 CJC-1295 studyOpen source →
Regulatory and trial recordsWorld Anti-Doping Agency
World Anti-Doping Agency: 2026 Prohibited ListOpen source →
CJC-1295 development and human evidencePubMed
Jetté and colleagues: CJC-1295 albumin bioconjugates and receptor activityOpen source →
CJC-1295 development and human evidencePubMed
Teichman and colleagues: prolonged growth hormone and IGF-1 stimulation in healthy adultsOpen source →
CJC-1295 development and human evidencePubMed
Ionescu and Frohman: growth-hormone pulsatility during CJC-1295 exposureOpen source →
CJC-1295 development and human evidencePubMed
Sackmann-Sala and colleagues: serum-protein changes after CJC-1295Open source →
CJC-1295 development and human evidencePubMed
Alba and colleagues: CJC-1295 in GHRH-knockout miceOpen source →
Background, manufacture and analytical researchPubMed
Guillemin and colleagues: isolation of human growth hormone-releasing factorOpen source →
Background, manufacture and analytical researchPubMed
Rivier and colleagues: characterisation of human growth hormone-releasing factorOpen source →
Background, manufacture and analytical researchPubMed
Frohman and colleagues: rapid enzymatic degradation of human GHRHOpen source →
Background, manufacture and analytical researchPubMed
Henninge and colleagues: identification of CJC-1295 in an unknown preparationOpen source →
Background, manufacture and analytical researchPubMed
Knoop and colleagues: detection of GHRH analogues in human plasmaOpen source →
Background, manufacture and analytical researchGoogle Patents
Patent: solid-phase synthesis method for a CJC-1295-related GHRH derivativeOpen source →

Research reviewed through September 2026.